References
- Fromming KH, Szejtli J. CDs in Pharmacy. Dordrecht, The Netherlands: Kluwer Academic Publishers. 1994:1–81.
- Duchene D, Wouessidjewe D. Pharmaceutical and medicinal applications of cyclodextrins.. In: Dumitriu S, editors. Polysaccharides in Medical Applications. New York: Marcel Dekker, 1996:575–602.
- Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin Drug Carrier Systems. Chem Rev, 98:2045–2076.
- Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
- Rajewski RA, Stella VJ. (1996). Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci, 85:1142–1169.
- Reddy MN, Rehana T, Ramakrishna S, Chowdhary KP, Diwan PV. (2004). Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci, 6:E7.
- Ozdemir N, Erkin J. (2012). Enhancement of dissolution rate and bioavailability of sulfamethoxazole by complexation with ß-cyclodextrin. Drug Dev Ind Pharm, 38:331–340.
- Lu Y, Zhang T, Tao J, Ji G, Wang S. (2009). Preparation, characterization, and pharmacokinetics of the inclusion complex of genipin-beta-cyclodextrin. Drug Dev Ind Pharm, 35:1452–1459.
- Szejtli J. (1994). Medicinal applications of cyclodextrins. Med Res Rev, 14:353–386.
- Pitha J. Cyclodextrin derivatives with enhanced solubility power and lower toxicity. Proc. of 9th Int. Symposium on Cyclodextrins, Santiago de Compostela. 1998:210–215.
- Yan Z, Xu W, Sun J, Liu X, Zhao Y, Sun Y et al. (2008). Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm, 34:632–641.
- Wang S, Ding Y, Yao Y. (2009). Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm, 35:808–813.
- Borghetti GS, Pinto AP, Lula IS, Sinisterra RD, Teixeira HF, Bassani VL. (2011). Daidzein/cyclodextrin/hydrophilic polymer ternary systems. Drug Dev Ind Pharm, 37:886–893.
- Cirri M, Righi MF, Maestrelli F, Mura P, Valleri M. (2009). Development of glyburide fast-dissolving tablets based on the combined use of cyclodextrins and polymers. Drug Dev Ind Pharm, 35:73–82.
- Isradipine capsules, United state pharmacopeia 29-NF 24, 1209.
- Horst FS, James MJ, Leonard MG. Clinical Pharmacokinetics of Isradipine. American Journal of Medicine 1988;81 (3B):80–89.
- Sustained release delivery of isradipine, USPTO patent application 20060210623.
- Higuchi T, Connors KA. Phase-solubility techniques.. In: Reilly CN, ed. Advances in Analytical Chemistry and Instrumentation. New York, NY: Wiley-Interscience 1965:117–212.
- Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48–49.
- Douglas AS, James HF, Stanley RC. Principles of Instrumental analysis. Australia: Thomson Brooks/Cole Publisher, 2007:894–906.
- Ryan JA. (1986). Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem: cilastatin sodium case. J Pharm Sci, 75:805–807.
- Calabrò ML, Tommasini S, Donato P, Raneri D, Stancanelli R, Ficarra P et al. (2004). Effects of alpha- and beta-cyclodextrin complexation on the physico-chemical properties and antioxidant activity of some 3-hydroxyflavones. J Pharm Biomed Anal, 35:365–377.